Evoke Pharma, Inc. (EVOK)
NASDAQ: EVOK · Real-Time Price · USD
4.900
-0.110 (-2.20%)
At close: Sep 26, 2025, 4:00 PM EDT
4.760
-0.140 (-2.86%)
After-hours: Sep 26, 2025, 6:56 PM EDT
Evoke Pharma Employees
Evoke Pharma had 3 employees as of December 31, 2024. The number of employees decreased by 1 or -25.00% compared to the previous year.
Employees
3
Change (1Y)
-1
Growth (1Y)
-25.00%
Revenue / Employee
$4,264,953
Profits / Employee
-$1,794,103
Market Cap
10.23M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
EVOK News
- 4 weeks ago - MAI Capital Management Announces Strategic Partnership with Evoke Advisors - Business Wire
- 4 weeks ago - Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship - GlobeNewsWire
- 5 weeks ago - Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book - GlobeNewsWire
- 7 weeks ago - Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038 - GlobeNewsWire
- 2 months ago - Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036 - GlobeNewsWire
- 4 months ago - Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025 - GlobeNewsWire
- 7 months ago - Evoke Pharma, Inc. (EVOK) Q4 2024 Earnings Call Transcript - Seeking Alpha